Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis

J Am Acad Dermatol. 2011 Sep;65(3):e102-e104. doi: 10.1016/j.jaad.2011.04.029.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Bosentan
  • Drug Therapy, Combination
  • Endothelin A Receptor Antagonists*
  • Fingers*
  • Humans
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors / administration & dosage*
  • Piperazines / administration & dosage*
  • Purines / administration & dosage
  • Scleroderma, Systemic / complications*
  • Sildenafil Citrate
  • Skin Ulcer / complications
  • Skin Ulcer / drug therapy*
  • Sulfonamides / administration & dosage*
  • Sulfones / administration & dosage*

Substances

  • Endothelin A Receptor Antagonists
  • Phosphodiesterase 5 Inhibitors
  • Piperazines
  • Purines
  • Sulfonamides
  • Sulfones
  • Sildenafil Citrate
  • Bosentan